Clinical Trials

31 enrolled

Triple Negative Breast Neoplasms

NCT07339059 2026-04-09

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

35 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04559230 2026-03-30

Sacituzumab Govitecan in Recurrent Glioblastoma

32 enrolled

CNS

Glioblastoma

NCT05884320 2026-03-20

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

30 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05833867 2026-03-13

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Phase 1 Recruiting

Localized Muscle Invasive Bladder Urothelial Carcinoma

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05581589 2026-02-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

18 enrolled

Urinary Bladder Neoplasms

NCT07063212 2026-02-19

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06963905 2026-02-17

SIMONE

60 enrolled

Triple Negative Breast Neoplasms

NCT05838521 2026-02-06

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Gynecologic

Uterine Cervical Neoplasms

NCT06263543 2025-12-26

SERIES

75 enrolled

Breast Neoplasms

NCT06065371 2025-12-19

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Phase 1 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

31 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

54 enrolled

Gynecologic

Ovarian Neoplasms, Uterine Neoplasms

NCT07251868 2025-11-26

Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study

Recruiting

100 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04724018 2025-11-04

Sacituzumab Govitecan Plus EV in Metastatic UC

106 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04230109 2025-10-14

NeoSTAR

260 enrolled

Triple Negative Breast Neoplasms

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

34 enrolled

BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

40 enrolled

Breast Cancer Metastatic

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06923826 2025-07-25

TROP2

32 enrolled

Head & Neck

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT07046455 2025-07-01

Trop-2 Targeted PET Probes in Advanced TNBC

Phase NA Recruiting

Triple Negative Breast Neoplasms

NCT06665178 2025-06-25

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Breast Neoplasms

NCT05552001 2025-06-11

ISIdE

Phase 3 Recruiting

96 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06991790 2025-05-28

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Recruiting

51 enrolled

Triple Negative Breast Neoplasms

NCT06055465 2025-05-15

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

37 enrolled

Lung Neoplasms

NCT06401824 2025-05-06

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

25 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06431633 2025-04-10

ARIAN

Phase 3 Recruiting

129 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT05770531 2025-04-04

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

160 enrolled

Triple Negative Breast Neoplasms

NCT06682728 2025-03-26

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

23 enrolled

Carcinoma, Transitional Cell

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

240 enrolled

Breast Neoplasms

NCT06667167 2025-01-17

First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

21 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06329869 2024-12-02

SG-ESCC

35 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06102824 2024-11-25

ORIENTA

252 enrolled

HER2-negative Breast Cancer

NCT06235216 2024-11-01

SETHY

42 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT06236269 2024-07-19

ACROSS-TROP2

50 enrolled

Breast Neoplasms

NCT06243393 2024-07-10

TROPHIT1

Phase 2/3 Recruiting

80 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06356519 2024-04-10

Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Recruiting

150 enrolled